Emergent BioSolutions Inc. (EBS)
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Russian plague outbreak could boost these under-the-radar pharma stocks
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
Emergent Biosolutions Q2 Earnings Call Highlights
Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and pricing pressure in the naloxone market are expected to weigh on sales of NARCAN.
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture
Emergent BioSolutions faces a sharp reset in 2026 guidance, with revenue projected at $720–$760 million, well below prior expectations. 2025 profitability was buoyed by favorable mix, cost controls, and a one-time $60 million order, but these drivers are not expected to recur. Competitive pressure on naloxone and uneven government procurement drive margin compression and revenue unpredictability, with adjusted EBITDA guided down to $135-$155 million in 2026.
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Emergent Biosolutions (EBS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out?
Emergent Biosolutions (EBS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
